Killer T cells could provide solution to development of universal flu vaccine

  • Koutsakos M, et al.
  • Nature Immunology
  • 18 Feb 2019

  • curated by Priscilla Lynch
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Groundbreaking research, published in Nature Immunology, has identified that killer T cells can fight all influenza viruses creating the potential for the development of a world-first universal, one-shot flu vaccine.

The collaborative international research team investigated the breadth of CD8+ T cell cross-recognition and provided evidence of CD8+ T cell cross-reactivity across A, B and C influenza virus (IAV, IBV, ICV) strains.

Using mass spectrometry they identified immunodominant CD8+ T cell epitopes from IBVs that were protective in mice and found memory CD8+ T cells directed against universal and influenza-virus-type-specific epitopes in the blood and lungs of healthy humans. Lung-derived CD8+ T cells displayed tissue-resident memory phenotypes. Notably, CD38+Ki67+CD8+ effector T cells directed against novel epitopes were readily detected in IAV- or IBV-infected pediatric and adult subjects.

The research team then attempted to find robust responses to those viral parts in healthy and influenza-infected subjects. “Our immunisation studies with the peptide responsible for activating the killer T cells revealed remarkably reduced levels of flu virus and inflammation in the airways,” study author Marios Koutsakos said.

The researchers are now examining immunity in high-risk ethnic groups, including indigenous Australians and Alaskans, who might not share the same immune response as those investigated by this study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.